Several proteoglycans have been found to be important in prostate cancer, including versican, decorin, biglycan, lumican, and syndecan-1 (summarised in Table 2), and data from a range of studies implicate proteoglycan alterations to prostate cancer cell survival and metastasis [105]. Here, DCN is linked to prostate carcinoma.